{"document_type": "article", "byline": {"person": [{"firstname": "Andrew", "organization": "", "lastname": "SORKIN", "role": "reported", "rank": 1, "middlename": "Ross"}], "original": "By ANDREW ROSS SORKIN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Andrew Ross Sorkin DealBook column examines role of activist investment firm ValueAct, founded by Jeffrey Ubben, in designing executive compensation policies at Valeant Pharmaceuticals; critics suggest ValueAct's support of J Michael Pearson as Valeant's chief executive laid path for aggressive accounting practices that, along with decision to significantly increase drug prices, have sparked federal investigations. ", "multimedia": [{"type": "image", "url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbWide-v2.jpg", "legacy": {"wide": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbWide-v2.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "899"}, "width": 600, "subtype": "xlarge", "height": 899}, {"type": "image", "url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"kicker": "DealBook Column", "content_kicker": "DealBook", "print_headline": "Another Firm Pays a Price for Its Supporting Role at Valeant", "main": "ValueAct Pays a Price for Its Supporting Role at Valeant"}, "print_page": "1", "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Executive Compensation", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "ValueAct Capital Partners", "is_major": "Y", "rank": "3", "name": "organizations"}, {"value": "Ubben, Jeffrey W", "is_major": "N", "rank": "4", "name": "persons"}, {"value": "Pearson, John Michael (1959- )", "is_major": "N", "rank": "5", "name": "persons"}, {"value": "Ackman, William A", "is_major": "N", "rank": "6", "name": "persons"}, {"value": "Accounting and Accountants", "is_major": "N", "rank": "7", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "8", "name": "subject"}], "snippet": "ValueAct deserves credit \u2014 or blame \u2014 for virtually everything that happened to Valeant Pharmaceuticals over nearly the last decade.", "source": "The New York Times", "lead_paragraph": "ValueAct deserves credit \u2014 or blame \u2014 for virtually everything that happened to Valeant Pharmaceuticals over nearly the last decade.", "word_count": "1095", "pub_date": "2016-03-29T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/03/29/business/dealbook/valueact-pays-a-price-for-its-supporting-role-at-valeant.html", "_id": "56f9d31538f0d874a87cb0c6"}